KINLYTIC SUMMARY
Kinlytic™
(urokinase for injection)
Kinlytic™ (urokinase for injection) is a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture. The principal active ingredient of Kinlytic™ is the low molecular weight form of urokinase, and consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons.
Kinlytic™ is indicated in adults:
- For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments.
- For the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures.
The diagnosis should be confirmed by objective means, such as pulmonary angiography or non-invasive procedures such as lung scanning.
|
NEWS HIGHLIGHTSMedia Articles Related to Kinlytic (Urokinase)
Hand-Held Computer May Help Improve Pulmonary Embolism Diagnosis
Source: IT / Internet / E-mail News From Medical News Today [2009.11.17]
Pulmonary embolism is a life-threatening condition most often caused by a blood clot breaking off from a vein and entering the circulatory system. While evidence-based guidelines exist to help physicians safely and efficiently evaluate patients with suspected pulmonary embolism, testing often differs from what is suggested. Researchers sought to determine if a computer program for use on a mobile, handheld device could improve diagnostic decision-making.
When Seconds Count: Interventional Radiology Treatment For Pulmonary Embolism Saves Lives
Source: Respiratory / Asthma News From Medical News Today [2009.11.12]
Catheter-directed therapy or catheter-directed thrombolysis--an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs--saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology.
Decision-Support Software Aid PE Diagnosis (CME/CE)
Source: MedPage Today Emergency Medicine [2009.11.16]
Hand-held computers and decision-support software improved diagnostic decision making for suspected pulmonary embolism, French researchers said.
Published Studies Related to Kinlytic (Urokinase)
Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial. [2009.07]
The purpose of this study was to assess whether regular instillation of urokinase during abscess drainage leads to an improved outcome compared to saline irrigation alone. One hundred patients referred for image-guided abdominal abscess drainage were randomized between thrice daily urokinase instillation or saline irrigation alone...
Use of urokinase in percutaneous drainage of large breast abscesses. [2009.04]
OBJECTIVE: The purpose of this study was to evaluate intracavitary urokinase therapy versus irrigation with a saline solution in percutaneous drainage of large breast abscesses... CONCLUSIONS: Percutaneous drainage of large breast abscesses in nonlactating women with intracavitary urokinase irrigation is a simple and safe procedure. It reduces the treatment time and improves the clinical course of patients more than conventional drainage with saline irrigation.
Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration. [2008.09]
Patients with diabetic foot ulceration and critical limb ischemia have a high risk of major amputation, especially if limbs can not be revascularized...
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. [2008.01.20]
PURPOSE: Fibrin deposition at the intraluminal surface of the indwelling part of the central venous catheter (CVC) surface increases the risk of CVC-related coagulase-negative staphylococci (CoNS) infection. Therefore, repetitive enzymatic dissolution of fibrin by urokinase might reduce the risk of CVC-related infection. We undertook this study to investigate whether three times weekly urokinase rinsing of CVC reduces the incidence or severity of CVC-related infections by CoNS in patients undergoing intensive cytotoxic treatment for hematologic malignancies... CONCLUSION: Three times weekly urokinase rinsing reduces the incidence of CVC-related CoNS infection in patients treated with intensive cytotoxic therapy for hematologic malignancies, with acceptable safety.
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. [2007.10]
BACKGROUND AND PURPOSE: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan was organized to determine the safety and clinical efficacy of intraarterial infusion of urokinase (UK) in patients with stroke within 6 hours of onset... CONCLUSIONS: The trial was aborted prematurely and the primary end point did not reach statistical significance. Nevertheless, the secondary analyses suggested that intraarterial fibrinolysis has the potential to increase the likelihood of excellent functional outcome.
Clinical Trials Related to Kinlytic (Urokinase)
Dornase Alfa and Urokinase for Kids With Pleural Empyema [Recruiting]
The purpose of this study is to determine whether intrapleural treatment with Dornase alfa
plus Urokinase improves clinical outcome compared to Urokinase alone in children with
complicated parapneumonic effusions
Urokinase Versus Video-Assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood [Recruiting]
A great controversy exists about which is the best method to perform the evacuation of the
collection. To evaluate which is the best initial treatment to drain complicated
parapneumonic empyema (stages II and III) in children: the present study raises a hypothesis
of equivalence between both arms of treatment (chest drainage plus intrapleural urokinase or
videothoracoscopic debridement).
Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy [Recruiting]
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an
immunocompromised state. The etiology of this remains uncertain. The investigators suspect
that individuals with malignancy have abnormalities involving certain factors that influence
the coagulation pathway.
The investigators plan to measure these factors prior to and after bronchoscopy.
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Recruiting]
RATIONALE: A6 may stop the growth of tumor cells by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying the side effects and how well A6 works in treating
patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or
primary peritoneal cancer.
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer [Recruiting]
This is a prospective, serum proteomics study of men who are to undergo prostate biopsy. The
purpose is to determine if proteomic profiles can be used to distinguish between men with
prostate cancer on biopsy from men with no cancer on biopsy.
|
